CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 39,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.45, for a total value of $680,550.00. Following the completion of the transaction, the chief executive officer directly owned 711,164 shares in the company, valued at $12,409,811.80. The trade was a 5.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Monday, February 23rd, Xingjuan Chao sold 2,084 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total value of $41,242.36.
• On Monday, January 5th, Xingjuan Chao sold 79,000 shares of CeriBell stock. The stock was sold at an average price of $21.27, for a total transaction of $1,680,330.00.

CeriBell Price Performance

CBLL stock traded down $0.09 during trading on Friday, reaching $17.80. The company’s stock had a trading volume of 43,242 shares, compared to its average volume of 344,490. The company has a market capitalization of $669.99 million, a P/E ratio of -12.11 and a beta of 1.12. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The company’s fifty day moving average is $20.84 and its 200-day moving average is $16.42. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $24.33.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The firm had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. On average, research analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on CBLL. BTIG Research reissued a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. Canaccord Genuity Group increased their target price on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, CeriBell has an average rating of “Moderate Buy” and an average price target of $24.67.

Institutional Investors Weigh In On CeriBell

Hedge funds have recently added to or reduced their stakes in the business. TimesSquare Capital Management LLC grew its stake in shares of CeriBell by 48.5% during the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock worth $14,927,000 after purchasing an additional 260,116 shares during the period. Geode Capital Management LLC lifted its position in shares of CeriBell by 55.4% during the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after buying an additional 159,698 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after acquiring an additional 3,502 shares during the period. Intech Investment Management LLC purchased a new stake in shares of CeriBell during the second quarter worth about $266,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of CeriBell by 6,424.8% during the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after acquiring an additional 374,179 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.